Retail Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Retail Press Releases.

Press releases published on October 12, 2026

Oct. 12, 2026

Kaplan Fox Advises DICK’s Sporting Goods, Inc. (NYSE: DKS) Investors of a Securities Class Action Deadline on November 3, 2026

Indeterminate GlobeNewswire

Oct. 12, 2026

Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026

Indeterminate GlobeNewswire

Oct. 12, 2026

Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C

Indeterminate GlobeNewswire

Oct. 12, 2026

National Pizza Month Survey: Americans Will Go to Great Lengths for the Perfect Pizza

Indeterminate GlobeNewswire

Oct. 12, 2026

Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026

Indeterminate GlobeNewswire

Oct. 12, 2026

USITC Institutes Investigation of Vertical Power Delivery (VPD) Modules and Computing Systems Infringing a Vicor Patent

Indeterminate GlobeNewswire

Oct. 12, 2026

Kaplan Fox Notifies Investors of Beta Bionics, Inc. (NASDAQ: BBNX) of a Securities Fraud Class Action Deadline on November 3, 2026

Indeterminate GlobeNewswire

Oct. 12, 2026

Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets

Indeterminate GlobeNewswire

Oct. 12, 2026

Kaplan Fox & Kilsheimer LLP Reminds UWM Holdings Corporation (NYSE: UWMC) Investors of the Approaching Lead Plaintiff Deadline on October 13, 2026

Indeterminate GlobeNewswire

Oct. 12, 2026

CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026

Indeterminate GlobeNewswire

Oct. 12, 2026

NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury

Indeterminate GlobeNewswire

Oct. 12, 2026

Microchip Expands Data Center Portfolio to Meet Evolving AI Infrastructure Demands

Indeterminate GlobeNewswire

Oct. 12, 2026

Is Marriage Still Worth It? Dr. John Delony Tackles the Question in New Book, “Building the Marriage You Want,” Now Available for Presale

Indeterminate GlobeNewswire

Oct. 12, 2026

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

Indeterminate GlobeNewswire

Oct. 12, 2026

Beacon Therapeutics Presents Data from Pivotal VISTA Trial of Laru-zova at AAO 2026

Indeterminate GlobeNewswire

Oct. 12, 2026

Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease

Indeterminate GlobeNewswire

Oct. 12, 2026

TTM Technologies Announces $400 Million in Planned Strategic Investments to Accelerate AI Infrastructure Capacity in China and Malaysia

Indeterminate GlobeNewswire

Oct. 12, 2026

Ethan Allen Mails Letter to Shareholders Detailing its Highly Qualified Nominees and Executable Growth Plan

Indeterminate GlobeNewswire

Oct. 12, 2026

APP Deadline News: The AppLovin Securities Class Action Deadline is Approaching on November 16 – Investors Notified to Contact BFA Law

Indeterminate GlobeNewswire

Oct. 12, 2026

GOOG, GOOGL Deadline News: The Alphabet Securities Class Action Deadline is Approaching on December 1 – Investors Notified to Contact BFA Law

Indeterminate GlobeNewswire